STOCK TITAN
  1. Home
  2. Sec-filings
  3. IMVT
  4. [Form 4] Immunovant, Inc. Insider Trading Activity

Immunovant (IMVT) director granted options and RSUs in new equity awards

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Immunovant, Inc. director Atul Pande received new equity awards as part of his compensation. He was granted stock options for 7,061 shares of common stock at an exercise price of $24.61 per share, expiring on April 7, 2036. He also received 13,880 shares of common stock in the form of restricted stock units. These RSUs and the option shares will vest on April 1, 2027, if he continues service with the company through that date. Following these awards, he holds 116,731 common shares directly and 20,000 common shares indirectly through a trust.

Positive

  • None.

Negative

  • None.
Insider Pande Atul
Role Director
Type Security Shares Price Value
Grant/Award Stock Option (right to buy) 7,061 $0.00 --
Grant/Award Common Stock 13,880 $0.00 --
holding Common Stock -- -- --
Holdings After Transaction: Stock Option (right to buy) — 7,061 shares (Direct); Common Stock — 116,731 shares (Direct); Common Stock — 20,000 shares (Indirect, By Trust)
Footnotes (1)
  1. These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan (the "Plan"). Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest in full on April 1, 2027, subject to the Reporting Person's continuous service to the Issuer as of such date. The Reporting Person may elect to defer settlement of the RSUs upon vesting, subject to the requirements of Rule 409A. These options were granted pursuant to the Plan. The shares underlying the options will vest on April 1, 2027, subject to the Reporting Person's continuous service to the Issuer as of such date.
Stock options granted 7,061 options Grant on April 7, 2026 to purchase common stock
Option exercise price $24.61 per share Exercise price for 7,061 stock options
Option expiration April 7, 2036 Expiry date of granted stock options
RSUs granted 13,880 shares Restricted stock units granted April 7, 2026
Vesting date April 1, 2027 Vesting for RSUs and option shares, subject to service
Direct common shares after grant 116,731 shares Direct Immunovant common stock ownership post-award
Indirect common shares by trust 20,000 shares Indirect holdings classified as “By Trust”
restricted stock units ("RSUs") financial
"These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan"
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
2019 Equity Incentive Plan financial
"These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan"
Rule 409A regulatory
"The Reporting Person may elect to defer settlement of the RSUs upon vesting, subject to the requirements of Rule 409A."
Stock Option (right to buy) financial
"security_title: "Stock Option (right to buy)""
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Pande Atul
(Last)(First)(Middle)
C/O IMMUNOVANT, INC.
1000 PARK FORTY PLAZA, SUITE 210
(Street)
DURHAM NORTH CAROLINA 27713
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Immunovant, Inc. [ IMVT ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
04/07/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock04/07/2026A13,880(1)A$0116,731D
Common Stock20,000IBy Trust
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy)$24.6104/07/2026A7,061 (2)04/07/2036Common Stock7,061$07,061D
Explanation of Responses:
1. These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan (the "Plan"). Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest in full on April 1, 2027, subject to the Reporting Person's continuous service to the Issuer as of such date. The Reporting Person may elect to defer settlement of the RSUs upon vesting, subject to the requirements of Rule 409A.
2. These options were granted pursuant to the Plan. The shares underlying the options will vest on April 1, 2027, subject to the Reporting Person's continuous service to the Issuer as of such date.
Remarks:
/s/ Tiago Girao, attorney-in-fact for Atul Pande04/09/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did Immunovant (IMVT) director Atul Pande report?

Director Atul Pande reported equity awards, not market trades. He received 7,061 stock options and 13,880 restricted stock units in Immunovant common stock as part of compensation, increasing his direct and indirect ownership positions.

How many Immunovant (IMVT) stock options were granted to Atul Pande?

He was granted stock options for 7,061 shares of Immunovant common stock. These options have an exercise price of $24.61 per share and expire on April 7, 2036, with vesting tied to continued service through April 1, 2027.

What restricted stock unit (RSU) award did Atul Pande receive from Immunovant (IMVT)?

He received 13,880 restricted stock units under Immunovant’s 2019 Equity Incentive Plan. Each RSU represents one share of common stock and will vest in full on April 1, 2027, assuming his continuous service with the company.

When do Atul Pande’s new Immunovant (IMVT) equity awards vest?

Both the 13,880 restricted stock units and the 7,061 option shares are scheduled to vest on April 1, 2027. Vesting requires that Atul Pande remain in continuous service with Immunovant through that date under the plan terms.

What are Atul Pande’s Immunovant (IMVT) shareholdings after these transactions?

After the reported awards, he directly owns 116,731 shares of Immunovant common stock. In addition, 20,000 shares are held indirectly through a trust, giving him both direct and indirect exposure to the company’s equity.

Were these Immunovant (IMVT) insider transactions open-market purchases or sales?

They were not open-market trades. The filing shows grant or award acquisitions: stock options and restricted stock units granted as compensation, with no reported buying or selling of shares on the open market.